Newsletter | New competition decisions within the pharma sector
Two recent cases show the continuing focus on the pharmaceutical sector by competition authorities in the EU. The European Court of Justice recently issued a preliminary ruling regarding dissemination of misleading information on adverse reactions resulting from a medicinal product in violation of competition law.
In another recent decision, the Danish Competition Council held that the pharmaceutical distributor, CD Pharma, had abused its dominant position by charging excessive prices.
Read newsletter as PDF